| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 381.6 | 387.3 | 319.1 |
| Other income | 2.7 | 4.7 | 1.0 |
| Total income | 384.3 | 392.0 | 320.1 |
| Profit before exceptional items & tax | 16.3 | 8.7 | 10.5 |
| Exceptional items | 0.0 | 0.9 | 0.0 |
| Profit before tax | 16.3 | 9.6 | 10.5 |
| Net profit | 16.3 | 9.6 | 10.5 |
| Operating margin | 4.2% | 2.4% | 3.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +55.20% |
|---|---|
| Net profit, quarter on quarter | +69.80% |
| Revenue, year on year | +19.60% |
| Operating profit, year on year | +43.20% |
| Operating profit, quarter on quarter | +177.60% |
NSE results filing, NSE: SOLARA. Figures extracted from the filing.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹739.15
- Market cap
- ₹3,552 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- -2192.7×Sector 50.4×
- Promoter holding
- 41.93%-0.07% QoQ
- FII holding
- 11.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences is notifying physical shareholders to update their PAN, KYC, and nomination details per SEBI circulars. This is a routine regulatory compliance intimation.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026. Shareholders transacted business, including approving related party transactions.
Solara Active Pharma Sciences Earnings Call Transcript: Key Takeaways
Solara achieved record EBITDA/PAT despite significant geopolitical headwinds in West Asia impacting raw material costs.
- Call
- Guides 10% growth
Solara Active Pharma Sciences Earnings Call: Key Takeaways
Solara delivered its highest Q4 revenue in 8 quarters at INR 392cr, driven by a strong base business with 54% gross margins, despite persistent headwinds and negative EBITDA in the Ibuprofen segment.
Solara Active Pharma Sciences Earnings Call: Key Takeaways
Solara's base business shows strong momentum, hitting eight-quarter highs in revenue and EBITDA, yet the Ibuprofen segment remains a significant drag, forcing a strategic review and potential divestment of the vertical.
Solara Active Pharma Sciences Q4 FY26 Results: Turns Profitable, Net Profit ₹9.6 Cr
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹387.3 Cr (+41.9% YoY) and net profit of ₹9.6 Cr for Q4 FY26.
- Key figure
- Net profit ₹9.6 Cr